<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-129288" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Multiple Endocrine Neoplasias Type 4</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Ahmed</surname>
            <given-names>Fahad W.</given-names>
          </name>
          <aff>King Faisal Specialist Hospital and Research Center Madinah</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Majeed</surname>
            <given-names>Muhammad S.</given-names>
          </name>
          <aff>King Edward Medical University, Lahore</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Kirresh</surname>
            <given-names>Omar</given-names>
          </name>
          <aff>Royal Sussex County Hospital, Brighton</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Fahad Ahmed declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Muhammad Majeed declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Omar Kirresh declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>18</day>
          <month>10</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-129288.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Multiple endocrine neoplasia (MEN) constitutes a group of autosomal dominant disorders characterized by a broad spectrum of endocrine and nonendocrine diseases. MEN is divided into different types depending on the clinical presentations and genetic mutation.&#x000a0;MEN type 1 (MEN1) is the most common MEN syndrome.&#x000a0;MEN type 4 (MEN4) is a rare autosomal dominant endocrine tumor syndrome. The most common tumors seen in this condition involve the parathyroid glands, anterior pituitary, and gastro-entero-pancreatic neuroendocrine tissues. This activity&#x000a0;reviews the evaluation and management of MEN4 and highlights the role of the interprofessional team in improving outcomes for patients with this condition.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify&#x000a0;the etiology of MEN4.</p></list-item><list-item><p>Assess&#x000a0;the clinical presentation of MEN4.</p></list-item><list-item><p>Compare the management strategies of MEN4.</p></list-item><list-item><p>Implement some interprofessional strategies that can lead to better outcomes in patients with MEN4.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=129288&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=129288">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-129288.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Multiple endocrine neoplasia (MEN) constitutes a group of autosomal dominant disorders characterized by a broad spectrum of endocrine and nonendocrine diseases. Depending on the clinical presentations and genetic mutation, MEN is divided into different types. The most common syndrome is MEN type 1 (MEN1), characterized by primary hyperparathyroidism secondary to parathyroid gland hyperplasia, pituitary adenoma, and pancreatic neuroendocrine tumors.<xref ref-type="bibr" rid="article-129288.r1">[1]</xref></p>
        <p>MEN&#x000a0;type 2 (MEN2) is less common, divided into MEN2A and MEN2B, depending on clinical phenotype. MEN2A is characterized by medullary thyroid cancer, pheochromocytoma, and primary hyperparathyroidism; MEN2B is characterized by medullary thyroid cancer, pheochromocytoma, marfanoid features, and neuromas of lips, tongue, and colon.</p>
        <p>MEN&#x000a0;type 4 (MEN4) is the&#x000a0;most recently identified type of MEN. Although it shares a similar phenotype spectrum to MEN1, MEN4 is rare.<xref ref-type="bibr" rid="article-129288.r2">[2]</xref>&#x000a0;The difference between MEN1 and MEN4 lies in the germline gene mutation:&#x000a0;in MEN1, there is a mutation of the MEN1 gene; in MEN4,&#x000a0;there is a mutation in the cyclin-dependent kinase inhibitor 1B gene (<italic toggle="yes">CDKN1B</italic>).<xref ref-type="bibr" rid="article-129288.r2">[2]</xref>&#x000a0;Hyperparathyroidism is the primary clinical manifestation of MEN4, followed by pituitary adenomas. Less frequently, MEN4 may be associated with tumors of the adrenals, kidneys, and reproductive organs. Compared&#x000a0;with other types of MEN, such as MEN1, MEN4 is far less reported in the literature.<xref ref-type="bibr" rid="article-129288.r3">[3]</xref></p>
      </sec>
      <sec id="article-129288.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>Germline mutations in <italic toggle="yes">CDKN1B</italic> result in MEN4.&#x000a0;In humans, the <italic toggle="yes">CDKN1B</italic> gene is located on chromosome 12p13.1.<xref ref-type="bibr" rid="article-129288.r2">[2]</xref>&#x000a0;The <italic toggle="yes">CDKN1B</italic> gene encodes a protein called p27, a&#x000a0;CDK inhibitor (CDKI), a well-known cell-cycle regulator. <italic toggle="yes">CDKN1B</italic> functions as a tumor suppressor gene, and germline mutations in <italic toggle="yes">CDKN1B</italic> lead to reduced expression of p27, resulting in uncontrolled cell-cycle progression.<xref ref-type="bibr" rid="article-129288.r4">[4]</xref>&#x000a0;Conversely, in MEN1, there is an inactivation of menin (encoded by the <italic toggle="yes">MEN1</italic> gene)&#x000a0;that affects cell division&#x000a0;and gene transcription&#x000a0;of the&#x000a0;<italic toggle="yes">CDKN1B&#x000a0;</italic>regulator p27.<xref ref-type="bibr" rid="article-129288.r3">[3]</xref></p>
        <p>This mutation in <italic toggle="yes">CDKN1B</italic> was first identified in rats. Subsequently, Franklin&#x000a0;et al&#x000a0;tested their theory that CDKIs may work as tumor suppressor genes in mouse models.&#x000a0;They found that the loss of function of p18 and p27 leads to a wide range of multiple endocrine gland tumors that predominantly affect the pituitary, thyroid, adrenal, and parathyroid glands.<xref ref-type="bibr" rid="article-129288.r5">[5]</xref>&#x000a0;In 2002, Fritz et al described a MEN-like syndrome in rats with negative mutation for <italic toggle="yes">MEN1</italic> or <italic toggle="yes">RET</italic> genes.&#x000a0;This syndrome, involving multiple glands, was thought to be intermediate, or a combination of MEN1 and MEN2, and was termed "MENX."<xref ref-type="bibr" rid="article-129288.r6">[6]</xref>&#x000a0;</p>
        <p>In 2006, Pellegata et al mapped this locus of interest on the distal part of chromosome 4 in rats, including the <italic toggle="yes">CDKN1B</italic>&#x000a0;gene encoding the p27 protein, which has an autosomal recessive inheritance pattern in rats. In 2006, the same team reported the first case of MEN4 in humans&#x000a0;after studying&#x000a0;3 generations of a family with negative <italic toggle="yes">MEN1</italic> mutation but positive <italic toggle="yes">CDKN1B</italic> mutation with&#x000a0;multiple endocrine neoplasias and renal angiomyolipomas.<xref ref-type="bibr" rid="article-129288.r7">[7]</xref></p>
        <p>In 2008, MENX was renamed MEN4 at the 11th International Workshop on MENs in Delphi, Greece.<xref ref-type="bibr" rid="article-129288.r8">[8]</xref>&#x000a0;Frederiksen et al reviewed 29 cases published before June 2020 and suggested 16 mutations involved in MEN4 (12 missense, three small deletions, and one duplication).<xref ref-type="bibr" rid="article-129288.r3">[3]</xref> This suggests that MEN4 has an autosomal dominant inheritance in humans. The most common presentation is primary hyperparathyroidism due to parathyroid tumors, followed by pituitary tumors (functional and non-functional) and gastroenteropancreatic neuroendocrine tumors.</p>
      </sec>
      <sec id="article-129288.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>MEN4 is a new member of MEN syndromes&#x000a0;that shares phenotypical characteristics of MEN1 with a negative <italic toggle="yes">MEN1</italic> gene mutation. The estimated prevalence of MEN1 is exceptionally low: 0.02&#x000a0;to 0.2/1000.<xref ref-type="bibr" rid="article-129288.r9">[9]</xref>&#x000a0;The incidence of <italic toggle="yes">CDKN1B</italic> mutations in patients with MEN1-related neoplasia is challenging to estimate, but it is likely around 3%.<xref ref-type="bibr" rid="article-129288.r2">[2]</xref>&#x000a0;</p>
        <p>Given that very few cases of MEN4 are reported (and many are undiagnosed), the exact incidence and prevalence of MEN4 are uncertain. The age of onset is also not apparent; it may be earlier than in MEN1, but the evidence is conflicting, and additional&#x000a0;research is required for confirmation.<xref ref-type="bibr" rid="article-129288.r3">[3]</xref></p>
      </sec>
      <sec id="article-129288.s5" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>As previously discussed, MEN4 occurs due&#x000a0;to mutations in the&#x000a0;<italic toggle="yes">CDKN1B</italic> gene (located on chromosome 12p13.1), a tumor suppressor gene that encodes protein p27Kip1 (commonly called p27 or Kip1).<xref ref-type="bibr" rid="article-129288.r6">[6]</xref>&#x000a0;The&#x000a0;reduced expression of p27 by this mutation results in&#x000a0;uncontrolled cell-cycle progression.&#x000a0;The reported incidence of&#x000a0;<italic toggle="yes">CDKN1B</italic>&#x000a0;mutations in patients with a MEN1-related phenotype is 1% to 4%.<xref ref-type="bibr" rid="article-129288.r10">[10]</xref></p>
        <p>MEN4 can impact various glands and organ systems:&#x000a0;&#x000a0;</p>
        <p>
<bold>Parathyroid Gland</bold>
</p>
        <p>Primary hyperparathyroidism has been reported in up to 80% to 90% of cases with MEN4.<xref ref-type="bibr" rid="article-129288.r11">[11]</xref>&#x000a0;Primary hyperparathyroidism presents later in MEN4 compared&#x000a0;with MEN1, predominantly in females.<xref ref-type="bibr" rid="article-129288.r12">[12]</xref>&#x000a0;Only one case of recurrent hyperparathyroidism has been reported after parathyroidectomy, suggesting a milder disease spectrum than MEN1.<xref ref-type="bibr" rid="article-129288.r13">[13]</xref>&#x000a0;The histology of resected glands in MEN4&#x000a0;is consistent with parathyroid adenoma.<xref ref-type="bibr" rid="article-129288.r3">[3]</xref></p>
        <p>
<bold>Pituitary Gland</bold>
</p>
        <p>The second most common presentation of MEN4 is pituitary adenoma (nonfunctional and functional). It is proposed that 10% of patients with MEN4 have acromegaly, and 5% have Cushing disease. These findings are similar to those for MEN1.<xref ref-type="bibr" rid="article-129288.r3">[3]</xref>&#x000a0;A recent study found that 2.6% of patients with Cushing disease have the <italic toggle="yes">CDKN1B</italic> mutation.<xref ref-type="bibr" rid="article-129288.r14">[14]</xref>&#x000a0;Prolactinomas are rare in MEN4.<xref ref-type="bibr" rid="article-129288.r3">[3]</xref></p>
        <p>
<bold>Pancreas</bold>
</p>
        <p>The prevalence of gastrinomas and nonfunctional pancreatic tumors in MEN4 is approximately 25%. This is much lower than in MEN1. No case reports of insulinoma, vasoactive intestinal peptide-secreting tumor (VIPoma), glucagonoma, or ectopic adrenocorticotropic hormone (ACTH)&#x02013;secreting neuroendocrine tumors exist in MEN4 cases.<xref ref-type="bibr" rid="article-129288.r4">[4]</xref></p>
        <p>
<bold>Other&#x000a0;</bold>
</p>
        <p>There have also been reports of adrenal tumors, testicular cancer, cervical carcinoma, papillary thyroid cancer, colon cancer, carcinoid, and meningioma associated with MEN4.<xref ref-type="bibr" rid="article-129288.r3">[3]</xref><xref ref-type="bibr" rid="article-129288.r4">[4]</xref>&#x000a0;A recent report presented 2 cases with multiple immunological abnormalities, including myasthenia gravis, Sj&#x000f6;gren syndrome, type III cryoglobulinemia, autoimmune thyroiditis, and Crohn disease. Additionally, one of the patients had an adrenal nodule, causing autonomous cortisol secretion.<xref ref-type="bibr" rid="article-129288.r15">[15]</xref></p>
      </sec>
      <sec id="article-129288.s6" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>A detailed and comprehensive family history is essential&#x000a0;when evaluating those with suspected MEN4. This is because MEN4 has a heterogeneous phenotypic expression that can lead to different syndrome manifestations within members of the same family.</p>
        <p>It&#x000a0;is also important to&#x000a0;assess patients for hypercalcemia symptoms due to primary hyperparathyroidism and its associated clinical complications&#x000a0;(eg, renal calculi and osteoporosis);&#x000a0;signs and symptoms of nonfunctional and functional pituitary tumors&#x000a0;(eg, visual changes); and signs and symptoms of&#x000a0;neuroendocrine gastropancreatic tumors&#x000a0;(eg, heartburn).</p>
        <p>Past&#x000a0;medical history should be evaluated, with specific inquiries&#x000a0;about peptic ulcers, cancer (especially breast and reproductive organs), and surgical history.&#x000a0;</p>
        <p>Physical examination involves assessing for signs of hyperfunctioning pituitary disease, visual-field defects, neck masses, previous surgical scars, and autoimmune diseases. To date, there have not been reports of skin manifestations in MEN4. Furthermore, physical examination can be normal in some patients,&#x000a0;reinforcing the need for a detailed&#x000a0;personal and family history for diagnosis.</p>
      </sec>
      <sec id="article-129288.s7" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>MEN4 is phenotypically very similar to MEN1; therefore, the evaluation (laboratory and radiological) of MEN4 to screen for associated clinical conditions is similar to MEN1. Investigations evaluate parathyroid, pituitary, neuroendocrine, and reproductive organ tumors. Carcinoid tumors and meningioma can also occur in patients with MEN4.&#x000a0;</p>
        <p>Specifically, evaluations should focus on the following:</p>
        <p>
<bold>Parathyroid Gland</bold>
</p>
        <p>Primary hyperparathyroidism is the most common presentation of MEN4. Biochemical investigations include calcium, parathyroid hormone, vitamin D, 24-hour urine calcium, and creatinine to confirm the diagnosis; after that, an ultrasound of the parathyroid glands is recommended. If the parathyroid ultrasound result is unclear, a <sup>99m</sup>technetium (<sup>99m</sup>Tc)&#x000a0;sestamibi scan should be undertaken.</p>
        <p>If both parathyroid ultrasound and&#x000a0;<sup>99m</sup>Tc sestamibi scan are unclear, parathyroid four-dimensional (4D) computed tomography (CT) can be considered. It is suggested that screening for hyperparathyroidism with calcium and parathyroid hormone should be initiated at age 15 years in patients with confirmed MEN4.<xref ref-type="bibr" rid="article-129288.r3">[3]</xref>&#x000a0;A bone-density scan (dual-energy x-ray absorptiometry [DXA]) can be considered to evaluate bone density.</p>
        <p>
<bold>Pituitary Gland</bold>
</p>
        <p>Evaluation of the pituitary gland is mainly limited to undertaking biochemical testing of anterior pituitary hormones; these include&#x000a0;growth hormone (GH), insulin-like growth factor-1 (IGF-1), cortisol, ACTH, prolactin (PRL), follicle-stimulating hormone (FSH), luteinizing hormone (LH), thyroid-stimulating hormone (TSH), and thyroxine (T4). As mentioned above, acromegaly and Cushing disease are more common in MEN4.</p>
        <p>Dynamic testing, such as an oral glucose tolerance test for growth hormone excess and an overnight dexamethasone suppression test for cortisol excess, can be undertaken if initial history or initial investigation is suggestive of hormone excess. Prolactinomas are rare in MEN4, but nonfunctioning pituitary adenomas can occur,&#x000a0;causing&#x000a0;pressure effects or hypopituitarism; accordingly, visual fields may need to be assessed. Radiological evaluation of the pituitary gland includes magnetic resonance imaging (MRI) of the pituitary. Screening investigations (biochemical and radiological) for pituitary pathology can be initiated in adolescence.<xref ref-type="bibr" rid="article-129288.r3">[3]</xref></p>
        <p>
<bold>Pancreas</bold>
</p>
        <p>Only a few cases of gastrointestinal and pancreatic neuroendocrine tumors are reported in MEN4. Gastrinomas are the most common functional tumors in MEN4. Screening for&#x000a0;gastrointestinal and pancreatic neuroendocrine tumors should be initiated as per MEN1.<xref ref-type="bibr" rid="article-129288.r11">[11]</xref><xref ref-type="bibr" rid="article-129288.r16">[16]</xref>&#x000a0;</p>
        <p>It is recommended to&#x000a0;check&#x000a0;fasting gastrointestinal hormones annually, including gastrin, chromogranin A, pancreatic polypeptide, vasointestinal polypeptide, glucagon, and fasting glucose level C-peptide and insulin. Radiological investigations, including CT, MRI, endoscopic ultrasound, octreotide scan, and&#x000a0;<sup>68</sup>Ga-labelled DOTA<sup>0</sup>-Tyr<sup>3</sup>&#x000a0;octreotide (<sup>68</sup>Ga-DOTATOC) positron emission tomography (PET), can be undertaken depending on local availability and preference.<xref ref-type="bibr" rid="article-129288.r11">[11]</xref>&#x000a0;</p>
        <p>
<bold>Other Organs</bold>
</p>
        <p>As previously discussed, MEN4 can affect multiple other organs; however, due to the paucity of literature on MEN4, it is difficult to provide any guidance regarding evaluating tumors in other organs. Therefore, evaluation should be based on clinical judgment and performed on a case-by-case basis.&#x000a0;&#x000a0;</p>
        <p>
<bold>Genetic Analysis</bold>
</p>
        <p>MEN4 screening should be&#x000a0;performed in all patients with MEN1 in the absence of MEN1 gene mutation. All first-degree relatives of patients with MEN4 should be offered genetic testing.<xref ref-type="bibr" rid="article-129288.r4">[4]</xref>&#x000a0;One such test is the <italic toggle="yes">CDKN1B</italic> gene.</p>
      </sec>
      <sec id="article-129288.s8" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>The treatment and management of MEN4 is dependent upon where it presents:</p>
        <p>
<bold>Parathyroid Gland</bold>
</p>
        <p>Currently, there is no specific guidance with regard to the treatment of primary hyperparathyroidism in MEN4. The indication for surgery (parathyroidectomy) remains similar to the MEN1 guidelines.<xref ref-type="bibr" rid="article-129288.r4">[4]</xref><xref ref-type="bibr" rid="article-129288.r11">[11]</xref>&#x000a0;It is important to individualize surgical treatment. Furthermore, surgery should be carried out by an experienced endocrine surgeon.</p>
        <p>
<bold>Pituitary Gland</bold>
</p>
        <p>Management of pituitary adenoma in MEN4 is similar to that of non-MEN4 pituitary tumors. Transsphenoidal surgery is undertaken if the pituitary tumor is functional or causes a visual-field defect. Medical treatment includes somatostatin receptor analogs (octreotide or lanreotide) for acromegaly and dopamine agonists (cabergoline or bromocriptine) for prolactinomas. Radiotherapy can be considered if the pituitary tumor has aggressive features on radiological or histological examination.</p>
        <p>
<bold>Pancreas</bold>
</p>
        <p>The management approach for nonfunctional or functional neuroendocrine gastropancreatic tumors is similar to that of MEN1. These tumors can cause peptic ulceration due to excess secretion of gastric acid. The clinical syndrome is known as Zollinger-Ellison syndrome. Surgical resection may be curative if the tumor is fully excised and nonmetastatic. Medical treatment includes proton pump inhibitors and somatostatin analogs. There are no reported cases of&#x000a0;insulinoma, VIPoma, glucagonoma, or ectopic ACTH-secreting neuroendocrine tumors in MEN4.<xref ref-type="bibr" rid="article-129288.r3">[3]</xref></p>
        <p>
<bold>Others</bold>
</p>
        <p>The management approach for other clinical manifestations (adrenal tumor, thyroid, testicular cancer, carcinoid, meningioma, colon cancer) is based on the organ affected. Unfortunately, there is no specific guidance due to the lack of literature.</p>
      </sec>
      <sec id="article-129288.s9" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <p>Differential diagnosis includes MEN1, neurofibromatosis type 1, tuberous sclerosis, von Hippel-Lindau syndrome, and isolated primary hyperparathyroidism.</p>
      </sec>
      <sec id="article-129288.s10" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>Current evidence is too limited to conclude the prognosis of MEN4, and disease&#x000a0;onset is still to be elucidated. According to Frederiksen et al,&#x000a0;disease onset in MEN4 might be earlier than in MEN1.<xref ref-type="bibr" rid="article-129288.r3">[3]</xref>&#x000a0;However, de Laat et al found that those with the MEN1 phenotype, which was mutation-negative, developed manifestations later in life and had improved life expectancy.<xref ref-type="bibr" rid="article-129288.r17">[17]</xref>&#x000a0;Although this group may have had MEN4, conclusions cannot be drawn. As additional cases of MEN4 are diagnosed, this area of the debate will have more definite answers.</p>
      </sec>
      <sec id="article-129288.s11" sec-type="Complications">
        <title>Complications</title>
        <p>Complications associated with MEN4 are related to the disease burden and post-surgical complications.&#x000a0;Complications related to endocrine disease burden involve systemic and metabolic effects of acromegaly, Cushing disease, primary hyperparathyroidism, and functional gastropancreatic tumors.</p>
        <p>Primary hyperparathyroidism can result in osteoporosis and renal calculi. Pituitary disorders can reduce visual acuity, visual field defects, hypopituitarism, and associated manifestations.</p>
      </sec>
      <sec id="article-129288.s12" sec-type="Deterrence and Patient Education">
        <title>Deterrence and Patient Education</title>
        <p>MEN4 is a rare disorder causing tumors of multiple endocrine glands. The patient should be counseled regarding the impact of genetic testing. Patients&#x000a0;should be provided education regarding the spectrum of clinical disorders and their impact on them and their families.</p>
        <p>The patient should be encouraged to discuss the diagnosis with their family and undertake genetic testing. The patient and their family member should be able to discuss the diagnosis with a clinical geneticist or the genetic team. The patient and their family members should be advised to attend follow-up appointments regularly.</p>
      </sec>
      <sec id="article-129288.s13" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>MEN4 is a rare condition causing tumors of multiple endocrine glands. The spectrum of endocrine gland tumors is similar to MEN1, making it essential to differentiate the&#x000a0;2 through genetic testing. To date, very few cases of MEN4 have been reported. As a result, the&#x000a0;magnitude of the disease is not fully understood. To optimize outcomes, the management of these patients should be undertaken by an expert multidisciplinary and interprofessional team that includes primary care clinicians, specialists, nursing staff, and pharmacists (particularly an oncology-specialized pharmacist) in a tertiary care center.</p>
      </sec>
      <sec id="article-129288.s14">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=129288&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=129288">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/hormones-and-body-chemistry/multiple-endocrine-neoplasias-type-4/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=129288">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/129288/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=129288">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-129288.s15">
        <title>References</title>
        <ref id="article-129288.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Al-Salameh</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Baudry</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Cohen</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Update on multiple endocrine neoplasia Type 1 and 2.</article-title>
            <source>Presse Med</source>
            <year>2018</year>
            <month>Sep</month>
            <volume>47</volume>
            <issue>9</issue>
            <fpage>722</fpage>
            <page-range>722-731</page-range>
            <pub-id pub-id-type="pmid">29909163</pub-id>
          </element-citation>
        </ref>
        <ref id="article-129288.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Thakker</surname>
                <given-names>RV</given-names>
              </name>
            </person-group>
            <article-title>Multiple endocrine neoplasia type 1 (MEN1) and type 4 (MEN4).</article-title>
            <source>Mol Cell Endocrinol</source>
            <year>2014</year>
            <month>Apr</month>
            <day>05</day>
            <volume>386</volume>
            <issue>1-2</issue>
            <fpage>2</fpage>
            <page-range>2-15</page-range>
            <pub-id pub-id-type="pmid">23933118</pub-id>
          </element-citation>
        </ref>
        <ref id="article-129288.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Frederiksen</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Rossing</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Hermann</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Ejersted</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Thakker</surname>
                <given-names>RV</given-names>
              </name>
              <name>
                <surname>Frost</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Clinical Features of Multiple Endocrine Neoplasia Type 4: Novel Pathogenic Variant and Review of Published Cases.</article-title>
            <source>J Clin Endocrinol Metab</source>
            <year>2019</year>
            <month>Sep</month>
            <day>01</day>
            <volume>104</volume>
            <issue>9</issue>
            <fpage>3637</fpage>
            <page-range>3637-3646</page-range>
            <pub-id pub-id-type="pmid">30990521</pub-id>
          </element-citation>
        </ref>
        <ref id="article-129288.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Alrezk</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Hannah-Shmouni</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Stratakis</surname>
                <given-names>CA</given-names>
              </name>
            </person-group>
            <article-title>MEN4 and <italic>CDKN1B</italic> mutations: the latest of the MEN syndromes.</article-title>
            <source>Endocr Relat Cancer</source>
            <year>2017</year>
            <month>Oct</month>
            <volume>24</volume>
            <issue>10</issue>
            <fpage>T195</fpage>
            <page-range>T195-T208</page-range>
            <pub-id pub-id-type="pmid">28824003</pub-id>
          </element-citation>
        </ref>
        <ref id="article-129288.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Franklin</surname>
                <given-names>DS</given-names>
              </name>
              <name>
                <surname>Godfrey</surname>
                <given-names>VL</given-names>
              </name>
              <name>
                <surname>O'Brien</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Deng</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Xiong</surname>
                <given-names>Y</given-names>
              </name>
            </person-group>
            <article-title>Functional collaboration between different cyclin-dependent kinase inhibitors suppresses tumor growth with distinct tissue specificity.</article-title>
            <source>Mol Cell Biol</source>
            <year>2000</year>
            <month>Aug</month>
            <volume>20</volume>
            <issue>16</issue>
            <fpage>6147</fpage>
            <page-range>6147-58</page-range>
            <pub-id pub-id-type="pmid">10913196</pub-id>
          </element-citation>
        </ref>
        <ref id="article-129288.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fritz</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Walch</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Piotrowska</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Rosemann</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Sch&#x000e4;ffer</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Weber</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Timper</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Wildner</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Graw</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>H&#x000f6;fler</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Atkinson</surname>
                <given-names>MJ</given-names>
              </name>
            </person-group>
            <article-title>Recessive transmission of a multiple endocrine neoplasia syndrome in the rat.</article-title>
            <source>Cancer Res</source>
            <year>2002</year>
            <month>Jun</month>
            <day>01</day>
            <volume>62</volume>
            <issue>11</issue>
            <fpage>3048</fpage>
            <page-range>3048-51</page-range>
            <pub-id pub-id-type="pmid">12036912</pub-id>
          </element-citation>
        </ref>
        <ref id="article-129288.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pellegata</surname>
                <given-names>NS</given-names>
              </name>
            </person-group>
            <article-title>MENX.</article-title>
            <source>Ann Endocrinol (Paris)</source>
            <year>2012</year>
            <month>Apr</month>
            <volume>73</volume>
            <issue>2</issue>
            <fpage>65</fpage>
            <page-range>65-70</page-range>
            <pub-id pub-id-type="pmid">22542001</pub-id>
          </element-citation>
        </ref>
        <ref id="article-129288.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Alevizaki</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Stratakis</surname>
                <given-names>CA</given-names>
              </name>
            </person-group>
            <article-title>Multiple endocrine neoplasias: advances and challenges for the future.</article-title>
            <source>J Intern Med</source>
            <year>2009</year>
            <month>Jul</month>
            <volume>266</volume>
            <issue>1</issue>
            <fpage>1</fpage>
            <page-range>1-4</page-range>
            <pub-id pub-id-type="pmid">19522821</pub-id>
          </element-citation>
        </ref>
        <ref id="article-129288.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Goudet</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Bonithon-Kopp</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Murat</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ruszniewski</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Niccoli</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>M&#x000e9;n&#x000e9;gaux</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Chabrier</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Borson-Chazot</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Tabarin</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Bouchard</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Cadiot</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Beckers</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Guilhem</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Chabre</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Caron</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Du Boullay</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Verges</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Cardot-Bauters</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Gender-related differences in MEN1 lesion occurrence and diagnosis: a cohort study of 734 cases from the Groupe d'etude des Tumeurs Endocrines.</article-title>
            <source>Eur J Endocrinol</source>
            <year>2011</year>
            <month>Jul</month>
            <volume>165</volume>
            <issue>1</issue>
            <fpage>97</fpage>
            <page-range>97-105</page-range>
            <pub-id pub-id-type="pmid">21551167</pub-id>
          </element-citation>
        </ref>
        <ref id="article-129288.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Agarwal</surname>
                <given-names>SK</given-names>
              </name>
              <name>
                <surname>Mateo</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Marx</surname>
                <given-names>SJ</given-names>
              </name>
            </person-group>
            <article-title>Rare germline mutations in cyclin-dependent kinase inhibitor genes in multiple endocrine neoplasia type 1 and related states.</article-title>
            <source>J Clin Endocrinol Metab</source>
            <year>2009</year>
            <month>May</month>
            <volume>94</volume>
            <issue>5</issue>
            <fpage>1826</fpage>
            <page-range>1826-34</page-range>
            <pub-id pub-id-type="pmid">19141585</pub-id>
          </element-citation>
        </ref>
        <ref id="article-129288.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Thakker</surname>
                <given-names>RV</given-names>
              </name>
              <name>
                <surname>Newey</surname>
                <given-names>PJ</given-names>
              </name>
              <name>
                <surname>Walls</surname>
                <given-names>GV</given-names>
              </name>
              <name>
                <surname>Bilezikian</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Dralle</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Ebeling</surname>
                <given-names>PR</given-names>
              </name>
              <name>
                <surname>Melmed</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Sakurai</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Tonelli</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Brandi</surname>
                <given-names>ML</given-names>
              </name>
              <collab>Endocrine Society</collab>
            </person-group>
            <article-title>Clinical practice guidelines for multiple endocrine neoplasia type 1 (MEN1).</article-title>
            <source>J Clin Endocrinol Metab</source>
            <year>2012</year>
            <month>Sep</month>
            <volume>97</volume>
            <issue>9</issue>
            <fpage>2990</fpage>
            <page-range>2990-3011</page-range>
            <pub-id pub-id-type="pmid">22723327</pub-id>
          </element-citation>
        </ref>
        <ref id="article-129288.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lee</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Pellegata</surname>
                <given-names>NS</given-names>
              </name>
            </person-group>
            <article-title>Multiple endocrine neoplasia type 4.</article-title>
            <source>Front Horm Res</source>
            <year>2013</year>
            <volume>41</volume>
            <fpage>63</fpage>
            <page-range>63-78</page-range>
            <pub-id pub-id-type="pmid">23652671</pub-id>
          </element-citation>
        </ref>
        <ref id="article-129288.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tonelli</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Giudici</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Giusti</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Marini</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Cianferotti</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Nesi</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Brandi</surname>
                <given-names>ML</given-names>
              </name>
            </person-group>
            <article-title>A heterozygous frameshift mutation in exon 1 of CDKN1B gene in a patient affected by MEN4 syndrome.</article-title>
            <source>Eur J Endocrinol</source>
            <year>2014</year>
            <month>Aug</month>
            <volume>171</volume>
            <issue>2</issue>
            <fpage>K7</fpage>
            <page-range>K7-K17</page-range>
            <pub-id pub-id-type="pmid">24819502</pub-id>
          </element-citation>
        </ref>
        <ref id="article-129288.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chasseloup</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Pankratz</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Lane</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Faucz</surname>
                <given-names>FR</given-names>
              </name>
              <name>
                <surname>Keil</surname>
                <given-names>MF</given-names>
              </name>
              <name>
                <surname>Chittiboina</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Kay</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Hussein Tayeb</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Stratakis</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Mills</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Hern&#x000e1;ndez-Ram&#x000ed;rez</surname>
                <given-names>LC</given-names>
              </name>
            </person-group>
            <article-title>Germline CDKN1B Loss-of-Function Variants Cause Pediatric Cushing's Disease With or Without an MEN4 Phenotype.</article-title>
            <source>J Clin Endocrinol Metab</source>
            <year>2020</year>
            <month>Jun</month>
            <day>01</day>
            <volume>105</volume>
            <issue>6</issue>
            <fpage>1983</fpage>
            <page-range>1983-2005</page-range>
            <pub-id pub-id-type="pmid">32232325</pub-id>
          </element-citation>
        </ref>
        <ref id="article-129288.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chevalier</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Odou</surname>
                <given-names>MF</given-names>
              </name>
              <name>
                <surname>Demonchy</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Cardot-Bauters</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Vantyghem</surname>
                <given-names>MC</given-names>
              </name>
            </person-group>
            <article-title>Multiple Endocrine Neoplasia Type 4: Novel CDNK1B variant and immune anomalies.</article-title>
            <source>Ann Endocrinol (Paris)</source>
            <year>2020</year>
            <month>Jun</month>
            <volume>81</volume>
            <issue>2-3</issue>
            <fpage>124</fpage>
            <page-range>124-125</page-range>
            <pub-id pub-id-type="pmid">32386678</pub-id>
          </element-citation>
        </ref>
        <ref id="article-129288.r16">
          <label>16</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Singh</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Mulji</surname>
                <given-names>NJ</given-names>
              </name>
              <name>
                <surname>Jialal</surname>
                <given-names>I</given-names>
              </name>
            </person-group>
            <chapter-title>Multiple Endocrine Neoplasia Type 1</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>7</month>
            <day>10</day>
            <pub-id pub-id-type="pmid">30725665</pub-id>
          </element-citation>
        </ref>
        <ref id="article-129288.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>de Laat</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>van der Luijt</surname>
                <given-names>RB</given-names>
              </name>
              <name>
                <surname>Pieterman</surname>
                <given-names>CR</given-names>
              </name>
              <name>
                <surname>Oostveen</surname>
                <given-names>MP</given-names>
              </name>
              <name>
                <surname>Hermus</surname>
                <given-names>AR</given-names>
              </name>
              <name>
                <surname>Dekkers</surname>
                <given-names>OM</given-names>
              </name>
              <name>
                <surname>de Herder</surname>
                <given-names>WW</given-names>
              </name>
              <name>
                <surname>van der Horst-Schrivers</surname>
                <given-names>AN</given-names>
              </name>
              <name>
                <surname>Drent</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>Bisschop</surname>
                <given-names>PH</given-names>
              </name>
              <name>
                <surname>Havekes</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Vriens</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Valk</surname>
                <given-names>GD</given-names>
              </name>
            </person-group>
            <article-title>MEN1 redefined, a clinical comparison of mutation-positive and mutation-negative patients.</article-title>
            <source>BMC Med</source>
            <year>2016</year>
            <month>Nov</month>
            <day>15</day>
            <volume>14</volume>
            <issue>1</issue>
            <fpage>182</fpage>
            <pub-id pub-id-type="pmid">27842554</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
